Explore this article's sources with AI
Follow PeptideMethods on Google
Tirzepatide and WADA: Current Sport Status
Tirzepatide is not named on the 2026 WADA Prohibited List. Here is how named listing, catch-all scope, monitoring, and product risk differ.
Why we wrote this. Athletes need a current answer that does not confuse peptide chemistry with section S2 or invent a sanction precedent where official records do not support one.
In this article (6 sections)
Tirzepatide is not named as a prohibited substance on the 2026 World Anti-Doping Agency Prohibited List, which is the list in force on 3 November 2026. It also does not fit an obvious catch-all category on the face of that list. The careful answer is therefore that tirzepatide itself is not prohibited under the current WADA List, subject to checking the exact product, route, and competition rules with an anti-doping authority[1].
This conclusion is narrower than saying every product sold as tirzepatide is safe for an athlete to use. USADA tells athletes that the easiest way to check a medication is through Global DRO and notes that the WADA List is updated annually[2]. A prescription does not remove strict-liability duties, while a peptide label on a product does not establish what is actually in it.
No WADA section currently names tirzepatide
The 2026 List separates prohibited substances into sections. S2 covers peptide hormones, growth factors, related substances, and mimetics. S4 covers hormone and metabolic modulators. Tirzepatide is a GIP-receptor and GLP-1-receptor agonist used in authorised prescription products, but the word tirzepatide does not appear in the official 2026 List[1]. Neither section names the GLP-1 or GIP receptor agonist class as prohibited.
S0 also does not supply a shortcut to prohibition here. That section covers pharmacological substances with no current approval by a governmental regulatory health authority for human therapeutic use. Tirzepatide has FDA-approved products, including Mounjaro and Zepbound[3]. The fact that tirzepatide is a peptide does not by itself place it in WADA section S2, and the existence of metabolic effects does not automatically place every metabolic medicine in S4.
Named substances and catch-all language
Checking whether a drug is printed by name is only the first step. Several WADA sections cover named examples plus substances with similar chemical structures or biological effects. This prevents a newly marketed analogue from escaping a class rule merely because its name has not yet been added.
That catch-all logic should not be stretched without a documented basis. Section S2's related-substance language sits within defined groups such as erythropoietins, growth hormone pathways, and growth factors. Tirzepatide acts at GIP and GLP-1 receptors according to its FDA label[3]. We found no current WADA text that classifies this mechanism as similar to a prohibited S2 substance, and no official WADA or USADA source checked for this article assigns tirzepatide to S4.
This is the rare but important distinction: absence of a name is not always enough to establish permitted status, yet a catch-all cannot be invented just because a medicine affects hormones or metabolism. The classification needs to follow the actual words and scope of the List.
Monitoring is not the same as prohibition
WADA also publishes a Monitoring Program for substances it wants laboratories to track for patterns of use. The program is separate from the Prohibited List, and monitored substances are not prohibited merely because they are monitored. The official 2026 Monitoring Program does not name tirzepatide or semaglutide[4].
Athletes should still recheck annually. WADA says the latest List is published in October and takes effect on 1 January. The 2027 List had been published by this article's editorial date but was not yet in force. Status should be checked against the list that applies on the relevant date, not a screenshot or an old article.
Why there is no enforcement precedent here
The brief behind this article asked for a USADA enforcement precedent. We did not identify a current official USADA sanction announcement establishing an anti-doping rule violation for tirzepatide itself, so none is presented. A sanction involving another peptide or another GLP-1 medicine would not prove tirzepatide is prohibited.
That absence should not be converted into a promise that no athlete has ever faced an issue involving a mislabeled product, a prohibited co-ingredient, or a method violation. It means only that we are not using an unverified case to define the status of this named medicine.
The product and the method still matter
A prescribed, regulator-authorised tirzepatide product is not the same thing as an unverified product marketed online. Contamination or substitution can expose an athlete to a different prohibited substance. Athletes should avoid relying on seller labels and should use the medication-check process recommended by USADA[2].
Administration rules can also create a separate issue. WADA regulates some methods independently of the substance involved, including certain intravenous infusions or injections. Approved tirzepatide products are administered subcutaneously, but an athlete facing any nonstandard route or clinic procedure should check the method as well as the ingredient.
Practical reading for tested athletes
For an athlete subject to the WADA Code, the defensible workflow is to search the exact medication and country in Global DRO, keep a record of the result, and ask the relevant anti-doping organisation about any uncertainty. USADA's official Prohibited List page directs athletes to Global DRO and its Drug Reference Team[2]. A clinician should also know that the patient competes under anti-doping rules.
For more on pharmacology rather than sport rules, see how tirzepatide works. The broader tirzepatide reference page covers approved uses and safety context, while the United States tirzepatide regulation page tracks country-specific status. None of these pages substitutes for a current medication-status check tied to the athlete's jurisdiction and competition.
Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.
Frequently asked
Is tirzepatide prohibited by WADA in 2026?
Tirzepatide is not named on the 2026 WADA Prohibited List, and no current official WADA text checked for this article places its GIP and GLP-1 mechanism within a prohibited catch-all category.
Does being a peptide put tirzepatide in WADA section S2?
No. S2 covers defined peptide-hormone, growth-factor, related-substance, and mimetic groups. A medicine does not enter S2 solely because its molecule is a peptide.
Is tirzepatide on the 2026 WADA Monitoring Program?
No. The official 2026 Monitoring Program checked for this article does not name tirzepatide. Monitoring would not itself mean prohibition in any event.
How should a tested athlete check tirzepatide?
Search the exact medication and country in Global DRO, save the result, and contact the relevant anti-doping organisation if anything is unclear. Recheck when a new annual List takes effect.
Sources
- [1]World Anti-Doping Agency: current Prohibited List and searchable categoriesTier 1 · primary↩
- [2]USADA: WADA Prohibited List, annual update process, Global DRO and Drug Reference TeamTier 1 · primary↩
- [3]FDA openFDA label: Mounjaro (tirzepatide), approval and mechanism of actionTier 1 · primary↩
- [4]World Anti-Doping Agency: 2026 Monitoring ProgramTier 1 · primary↩
No revisions yet. First published .